reports
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financi...
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2023 and provided a corporate update. “As we enter 2024, we are financially strong, focused and motivated,” stated Dr. Neal Walker, co-founder and Interim Chief Executive Officer & President of...
Aclaris Therapeutics Announces Leadership Changes and Strategic Busine...
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review - Douglas Manion, M.D. to step down as Chief Executive Officer, President and Member of Board of Directors - - Dr. Neal Walker, Current Chairman and Co-founder, Appointed as Interim Chief Executive Officer - WAYNE, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced leadership changes and that it is undertaking a strategic review of its busines...
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b T...
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis - ATI-1777 2% BID Achieved a Statistically Significant Result in the Primary Efficacy Endpoint at Week 4 - - Minimal Systemic Exposure Supports “Soft” Topical JAK Inhibitor Approach - - ATI-1777 Was Well Tolerated - WAYNE, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced top-line results fro...
Aclaris Therapeutics Provides Corporate Update
Aclaris Therapeutics Provides Corporate Update - ATI-1777 Phase 2a Trial Results Published in JID Innovations -- ATI-1777 Phase 2b Trial Topline Data Anticipated in January 2024 -- Aclaris Announces Reduction in Workforce - WAYNE, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced several corporate updates. First, Aclaris announced the publication of the Phase 2a trial results of ATI-1777 in moderate to severe atopic dermatitis (AD...
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharm...
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc. (Sun Pharma). Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitinib, to tre...
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b ...
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update — Study Did Not Meet Primary or Secondary Efficacy Endpoints in Rheumatoid Arthritis — — Efficacy Results Do Not Support Further Development of Zunsemetinib — — Company to Host Conference Call and Webcast Today at 8:00 AM ET — WAYNE, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflamm...
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and ...
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update - Topline Data from Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis Expected this Month – - Completion of Enrollment in ATI-1777 Phase 2b Trial in Atopic Dermatitis As Previously Announced; Topline Data Anticipated Around Year-End 2023 - WAYNE, Pa., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for...
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-177...
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202) - Top-line Data Anticipated Around Year End WAYNE, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the completion of enrollment into ATI-1777-AD-202, its Phase 2b trial of its investigational topical “soft” Janus kinase (JAK) 1/3 inhibitor, ATI-1777, in patients with mild to severe atopic dermat...
Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthca...
Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference WAYNE, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 10:30 AM ET, in New York, NY. A webcast of the fireside chat may be accessed through the “Events” page of the “Invest...
Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple ...
Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor – Preliminary Data Support Progression to Phase 2a Proof of Concept Trials in T cell-mediated Autoimmune Diseases – WAYNE, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced positive results from ATI-2138-PKPD-102, a Phase 1 Multiple Ascending Dose (MAD) trial of the i...
Aclaris Therapeutics Inc: 1 director
A director at Aclaris Therapeutics Inc bought 9,490 shares at 7.900USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and...
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update - Completion of Enrollment in Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis As Previously Announced; Data Expected in Q4 2023 - WAYNE, Pa., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2023 and provided a corporate update. “During the second quarter of this year, we con...
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zu...
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202) - Topline Data Anticipated in Q4 2023 WAYNE, Pa., June 13, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the completion of enrollment into ATI-450-RA-202, its Phase 2b trial of oral zunsemetinib in patients with moderate to severe rheumatoid arthritis (RA). Aclaris expects to anno...
Aclaris Therapeutics to Participate in Two June Healthcare Investor Co...
Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences WAYNE, Pa., June 02, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in two healthcare investor conferences in June. Management will participate in a fireside chat during the 2023 Jefferies Global Healthcare Conference on Thursday, June 8, 2023 at 4:30 PM ET, in New York, NY. Additionally, mana...
Aclaris Therapeutics Reports First Quarter 2023 Financial Results and ...
Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update - Management to Host Conference Call at 8:00 AM ET Today – WAYNE, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2023 and provided a corporate update. “The first quarter of 2023 represented another period of continued progress advancing our clinical stage development programs ...
Aclaris Therapeutics to Announce First Quarter 2023 Financial Results ...
Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023 WAYNE, Pa., May 02, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced it will report financial results for the first quarter 2023 on Monday, May 8, 2023, before the opening of the U.S. financial markets. Management will conduct a conference call at 8:00 AM ET on the same day to discuss Aclaris’ financial results and to provide a corporate update, inclu...
Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune ...
Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference WAYNE, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30, 2023 at 1:00 PM ET. A webcast of the fireside chat may be accessed throu...
Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week P...
Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa - Study Did Not Meet Primary or Secondary Efficacy Endpoints in Hidradenitis Suppurativa- Overall Safety Profile and PK/PD Generally Consistent with Observations in Prior Studies of Zunsemetinib WAYNE, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced prelimin...
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financi...
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update WAYNE, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2022 and provided a corporate update. “The past year for Aclaris was marked by tremendous execution across our organization notably highlighted by our clinical development programs and our prop...
Aclaris Therapeutics to Participate in the Virtual SVB Securities Glob...
Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference WAYNE, Pa., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the Virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 9:20 AM ET. A webcast of the fireside chat may be accessed through the “Events” page of the “Invest...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.